Association between preoperative inflammatory status via CALLY index and postoperative pneumonia occurrence in resectable esophageal squamous cell carcinoma patients: a retrospective cohort study

Frontiers in Oncology, Год журнала: 2025, Номер 15

Опубликована: Фев. 17, 2025

Background Postoperative pneumonia significantly affects recovery and prognosis in patients with esophageal squamous cell carcinoma. The CALLY index, derived from preoperative hematological parameters, may serve as a predictive marker for such complications. Objectives To assess the association between inflammatory status via index occurrence of postoperative resectable ESCC. Methods A retrospective cohort study was conducted January 2020 to December 2022 at Affiliated Huai’an No. 1 People’s Hospital Nanjing Medical University. total 215 who met inclusion criteria were analyzed. Clinical data, including indices calculated preoperatively, collected. Propensity score matching applied minimize confounding biases. value assessed using receiver operating characteristic analysis, logistic regression used identify factors associated pneumonia. Results ROC curve analysis demonstrated had an area under 0.764 predicting pneumonia, cutoff 1.97 achieving 67.69% sensitivity 84.67% specificity. In multivariate lower increased risk, independent other (adjusted OR = 0.66, p < 0.001). High scores correlated decreased likelihood reinforcing its utility non-invasive prognostic marker. Conclusions is robust, predictor Preoperative assessment this could enhance risk stratification guide proactive management strategies improve outcomes.

Язык: Английский

Efficacy and prognosis biomarker of locally advanced ESCC patients treated with neoadjuvant chemotherapy and anti-PD-1 immunotherapy

Frontiers in Oncology, Год журнала: 2025, Номер 14

Опубликована: Фев. 19, 2025

Immunotherapy has rapidly advanced in tumor treatment. In esophageal squamous cell carcinoma (ESCC), its use neoadjuvant therapy shown promising results. Several phase III clinical trials have confirmed that immunodetection site inhibitors can enhance the pathologically complete response (pCR) rate. We retrospectively analyzed 128 ESCC patients treated with chemotherapy plus anti-PD-1 immunotherapy at Affiliated Cancer Hospital of Zhengzhou University and Henan from July 2019 to November 2023. Of patients, 31 (24.1%) achieved pCR, 46 (35.9%) a major pathological (MPR). Female low-level abnormal protein (TAP), moderate differentiation were significantly associated higher pCR rate MPR Besides rate, TAP had longer PFS OS. The mean group was 42.4 months, than 28.5 months high-level (p = 0.019). OS 43.7 compared 30.5 0.027). multivariate analysis showed independent prognostic factors for PFS, an factor anti-PD-1. Thus, lower levels predict better patients. practice, serum before serve as useful tool efficacy this combined

Язык: Английский

Neoadjuvant chemotherapy with or without PD-1/PD-L1 inhibitors in resectable esophageal squamous cell carcinoma: a meta-analysis based on randomized controlled trials

BMC Gastroenterology, Год журнала: 2025, Номер 25(1)

Опубликована: Май 29, 2025

Neoadjuvant chemotherapy (NC) is a cornerstone in the management of resectable esophageal squamous cell carcinoma (ESCC). The integration PD-1/PD-L1 inhibitors into NC (NIC) regimens has shown promise; however, its efficacy and safety remain uncertain. This meta-analysis aims to compare potential risks clinical benefits NIC versus patients with ESCC based on randomized controlled trials (RCTs). A thorough search six databases was performed identify RCTs evaluating ESCC. Key outcomes analyzed included pathological complete response (pCR) rate major (MPR) rate. Other overall survival (OS), event-free (EFS), surgery rate, R0 resection adverse events (AEs). Four encompassing 605 were included. significantly improved pCR (risk ratio [RR]: 2.66 [1.63, 4.34], P < 0.0001) MPR (RR: 1.74 [1.02, 2.95], = 0.04) compared group. Only one phase III RCT reported outcomes, showing that group demonstrated OS (HR: 0.48 [0.24, 0.96], EFS 0.62 [0.39, 0.99], 0.05). Additionally, 1.11 [1.03, 1.20], 0.008) number resected lymph nodes (mean difference [MD]: 3.91 [0.60, 7.21], 0.02) also higher duration surgery, intraoperative blood loss comparable between groups. However, immune-related AEs (irAEs) 40.80 [5.67, 293.37], 0.0002) Similar surgical complications observed two demonstrates superior improving alone, may potentially provide benefits, although it associated risk irAEs.

Язык: Английский